This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sunshine Heart Welcomes Dr. Patrick Verta As Chief Medical Officer

EDEN PRAIRIE, Minn., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) announced that, effective today, Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings over 20 years of experience in the medical field with the majority of time spent in the cardiovascular field.  

Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of Clinical Affairs at Neomend, a medical device company that developed and commercialized the only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The company was acquired by Bard/Davol in October 2012. Before Neomend, he served as Medical Director of Clinical Research and Business Development at Abbott Vascular, where he played a critical role in the approval of several stent systems used in peripheral vascular disease, in particular carotid artery stenosis, renal artery stenosis, and peripheral Artery Disease (PAD). While at Abbott, Dr. Verta led the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the largest randomized carotid trial ever, enrolling over 2,500 patients and considered today to be the gold standard for carotid stenting trials. Prior to Abbott, Dr. Verta held the position of Endovascular Clinical Science and Biometrics Director at Guidant Corporation.

In addition to his experience driving clinical trials, he has co-authored seventeen manuscripts on novel medical device therapies in peer-review journals, and is credited with two patents in the data management and electronic data capture areas. Dr. Verta holds a Doctorate of Medicine from the Faculté de Médecine in Paris, France; as well as a Doctorate of Veterinary Medicine from the Ecole Nationale Vétérinaire d'Alfort, France. He also completed a Masters Degree in Biostatistics at the University of Paris.

"We are pleased and fortunate to welcome Dr. Verta to Sunshine Heart as Chief Medical Officer," said Dave Rosa, Sunshine Heart's CEO. "His experience conducting large, complex clinical trials will be essential as we continue to progress within both our U.S. pivotal trial, COUNTER HF; as well as our European post-market study, OPTIONS HF. In particular, we look forward to his contributions toward accelerating and managing prudent site selection and enrollment with regard to both clinical trials going forward."  

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs